Creating Patient Value through Innovation

CGI has a strong and growing portfolio in molecular-focused patents for the diagnosis, prognosis and risk stratification of difficult-to-treat cancers. Our patents are based on unique algorithms that take into account multiple chromosomal regions associated with particular disease outcomes or treatment decision.

Methods of Analyzing Chromosomal Translocations Using Fluorescence In Situ Hybridization (FISH).

  • US Patent No. 7,585,964. Filed May 15, 2002
  • US Patent No. 7,964,345. Filed April 5, 2005.
  • Canadian Patent No. 2,447,320. Pub. Nov. 21, 2002.

Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms.

  • US 12/980,480. Filed Dec. 29, 2010.
  • US 13/475,034. Filed May 18, 2012.
  • European Patent Application Nos. 14199582.9 and 10803548.6. Filed Dec. 29, 2010.
  • Indian Patent Application No. 6657/DELNP/2012. Filed Dec. 29, 2010.
  • Canadian Patent Application No. 2,785,656. Filed Dec. 29, 2010.

Panel for the Detection and Differentiation of Renal Cortical Neoplasms.

  • US Patent No. 8,716,193. Filed Nov. 13, 2013.
  • US Patent No. 8,603,948. Filed Oct. 31, 2007.
  • European Patent Application Nos. 14193756.5 and 08844570.5. Filed Oct. 31, 2008.

Methods and Tools for the Diagnosis of Female Gynecological Cancers and Precancers.

  • US Patent Application No. 61/581,350. Filed Dec. 29, 2011.

Methods and Tools for the Diagnosis and Prognosis of Urogenital Cancers.

  • US Patent Application No. 61/765,678. Filed Feb. 15, 2013.

Methods for Detecting Human Papilloma Virus-Associated Cancers.

  • US Patent No. 9,157,129. Filed Sept. 23, 2014.
  • US Patent No. 8,883,414. Filed May 17, 2012.
  • US Patent No. 8,865,882.  Filed Sept. 7, 2011.
  • European Patent No. US/2012/0202200. Pub. Aug. 9, 2012.

Patent Family: Tissue of Origin® Test

 

PATENTS
 

Jurisdiction Title Patent No. Issue Date Status
United States Systems and Methods for Detecting Biological Features 8,977,506 March 10, 2015 Issued
United States Knowledge-based Storage of Diagnostic Models 8,321,137 November 27, 2012 Issued
United States Systems and Methods for Diagnosing a Biological Specimen Using Probabilities 7,747,547 June 29, 2010 Issued
United States Standards and Methods for Standardization of Microarray Data 8,473,217 June 25, 2013 Issued

Patent Family: KRAS Primers and Probes

Test type: PCR, NGS
Cancer type: lung, colon and thyroid

PATENTS 

Jurisdiction Title Patent No. Issue Date Status
China KRAS Primers and Probes CN102869790 November 26, 2014 Issued

Patent Family: ERCC1 and Cisplatin

Test type: rt-PCR
Cancer type: lung, colon and gastric 

PATENTS 

Jurisdiction Title Patent No. Issue Date
United States Method of determining a chemotherapeutic regimen based on ERCC1 expression 6,518,416 February 11, 2003
United States Method of determining a chemotherapeutic regimen based on ERCC1 expression 6,573,052 June 3, 2003
United States Method of determining a chemotherapeutic regimen based on ERCC1 expression 6,602,670 August 5, 2003
United States Method of determining a chemotherapeutic regimen based on ERCC1 expression 7,132,238 November 7, 2006
Australia Method of determining a chemotherapeutic regimen based on ERCC1 expression 2002249768 B2 April 19, 2007
Canada Method of determining a chemotherapeutic regimen based on ERCC1 expression 2,437,044 March 12, 2013
China Method of determining a chemotherapeutic regimen based on ERCC1 expression ZL01822442.3 March 7, 2012
EP (validated in Austria, Belgium, Switzerland, Lichtenstein, Germany, France, UK, Italy, Spain, Netherlands, Sweden and Ireland) Method of determining a chemotherapeutic regimen based on ERCC1 expression 1364054 September 25, 2013
Hong Kong Method of determining a chemotherapeutic regimen based on ERCC1 expression 1078328B September 14, 2012
Israel Method of determining the level of ERCC1 expression and use of chemotherapeutic regimen selected by a method in the preparation of a medicament 156272 April 1, 2014
Japan Method of determining a chemotherapeutic regimen based on ERCC1 expression 4503922 April 30, 2010
Korea Method of determining a chemotherapeutic regimen based on ERCC1 expression 10-966271 June 18, 2010
Korea Method of determining a chemotherapeutic regimen based on ERCC1 expression 10-1014345 February 7, 2011
Mexico Method of determining a chemotherapeutic regimen based on ERCC1 expression 287966 July 1, 2011
New Zealand Method of determining a chemotherapeutic regimen based on ERCC1 expression 526710 January 12, 2006
Taiwan Method of determining a chemotherapeutic regimen based on ERCC1 expression I321155 March 1, 2010

Patent Family: EGFR and Her-2-neu

Test type: Sanger sequencing, FISH
Cancer type: lung, colon

PATENTS

Jurisdiction Title Patent No. Issue Date
United States Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 6,582,919 June 24, 2003
Australia Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 2002232409 March 22, 2007
EP (validated in Austria, Belgium, Switzerland, Lichtenstein, Germany, France, UK, Italy, Spain, Netherlands, Sweden and Ireland) Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 1379686 September 5, 2012
Israel Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 156233 July 30, 2010
Israel Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 156233 December 1, 2012
Japan Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 4510915 May 14, 2010
Korea Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 10-946980 March 4, 2010
Korea Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 10-1014342 February 7, 2011
Mexico Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 282866 January 14, 2011
Mexico Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 293677 December 14, 2011
New Zealand Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 526709 September 11, 2008
New Zealand Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 546251 May 15, 2008
New Zealand Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates 546252 July 10, 2008
Taiwan Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates I313711 August 21, 2009
Taiwan Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates I312809 August 1, 2009
Taiwan Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereof with Survival Rates I321156 March 1, 2010

Patent Family: ERCC1 and TS

Test type: rt-PCR
Cancer type: lung, colon and gastric
 

PATENTS 

Jurisdiction Title Patent No. Issue Date
United States Method of determining achemotherapeutic regimen based on ERCC1 and TS expression 7,049,059 May 23, 2006
United States Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression 7,560,543 July 14, 2009
United States Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression 7,732,144 June 8, 2010
United States Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression 8,586,311 November 19, 2013
Argentina Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression AR031442 July 22, 2011
Australia Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression 2002246504 July 19, 2007
Canada Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression 2437038 February 11, 2014
China Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression ZL01822464.4 June 22, 2011
EP (validated in Austria, Belgium, Switzerland, Lichtenstein, Germany, France, UK, Italy, Spain, Netherlands, Sweden and Ireland) Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression 1381691 April 24, 2013
Mexico Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression 264888 March 3, 2009
Israel Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression 156232 October 1, 2010
New Zealand Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression 526711 December 14, 2006

 

Jurisdiction Title Patent No. Issue Date
Taiwan Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression I317759 December 1, 2009
Taiwan Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression I327598 July 21, 2010

Patent Family: Chemotherapy & Gene Expression in Primary Tumors

Test type: rt-PCR
Cancer type: lung, colon and gastric
 

PATENTS 

Jurisdiction Title Patent No. Issue Date
United States Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors 8,026,062 September 27, 2011
Taiwan Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors I319010 January 1, 2010

Patent Family: Method of Determining Dihydropyrimidine Dehydrogenase Gene Expression

(Tissue and Cancer Types Gene Expression)

PATENTS 

Jurisdiction Title Patent No. Issue Date
United States Method of determining dihydropyrimidine dehydrogenase gene expression 6,956,111 October 18, 2005
United States Method of determining dihydropyrimidine dehydrogenase gene expression 6,905,821 June 14, 2005
United States Method of determining dihydropyrimidine dehydrogenase gene expression 7,005,278 February 28,2006
Argentina Method of determining dihydropyrimidine dehydrogenase gene expression AR032917 April 30, 2010
Australia Method of determining dihydropyrimidine dehydrogenase gene expression 2002238115 September 27, 2007
Canada Method of determining dihydropyrimidine dehydrogenase gene expression 2439313 August 7, 2012
China Method of determining dihydropyrimidine dehydrogenase gene expression ZL02809318.6 April 12, 2006
China Method of determining dihydropyrimidine dehydrogenase gene expression ZL200610007076.2 October 6, 2010
China Method of determining dihydropyrimidine dehydrogenase gene expression ZL200610007077.7 December 8, 2010
EP (validated in Austria, Switzerland, Lichtenstein, Germany, France, UK, Netherlands and Ireland) Method of determining dihydropyrimidine dehydrogenase gene expression 1 409 723 B1 August 18, 2006
Hong Kong Method of determining dihydropyrimidine dehydrogenase gene expression HK1097571 August 5, 2011
Hong Kong Method of determining dihydropyrimidine dehydrogenase gene expression HK1097575 September 2, 2011
Hong Kong Method of determining dihydropyrimidine dehydrogenase gene expression HK1068375 October 27, 2006
Israel Method of determining dihydropyrimidine dehydrogenase gene expression 157694 March 1, 2011
Japan Method of determining dihydropyrimidine dehydrogenase gene expression 4690446 February 25, 2011
Korea Method of determining dihydropyrimidine dehydrogenase gene expression 10-909116 July 16, 2009
Mexico Method of determining dihydropyrimidine dehydrogenase gene expression 254799 February 15, 2008
New Zealand Method of determining dihydropyrimidine dehydrogenase gene expression 528374 May 15, 2008
Taiwan Method of determining dihydropyrimidine dehydrogenase gene expression I274076 February 21, 2007

Patent Family: Method of Determining a Chemotherapeutic Regimen Based on GST-pi Expression 

(Gene Expression)

PATENTS 

Jurisdiction Title Patent No. Issue Date
United States Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 6,686,155 February 3, 2004
United States Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 7,138,507 November 21, 2006
Argentina Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression AR034342 January 30, 2012

 

Jurisdiction Title Patent No. Issue Date
Australia Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 2002305573 April 23, 2009
Canada Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 2450257 November 6, 2012
China Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression ZL02815798.2 June 3, 2009
China Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression ZL20051010768 4.6 December 19, 2007
EP (validated in Austria, Belgium, Switzerland, Lichtenstein, Germany, France, UK, Italy, Spain, Netherlands, Sweden and Ireland) Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 1407047 January 22, 2014
Hong Kong Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 1070921 November 13, 2009
Israel Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 159301 September 17, 2010
Japan Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 4303104 May 1, 2009
Japan Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 4308309 May 15, 2009
Korea Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 10-918927 September 18, 2009
Mexico Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 284095 February 16, 2011
New Zealand Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 530520 February 8, 2007
Taiwan Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression I338049 March 1, 2011
Australia Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression 2002305573 April 23, 2009

Patent Family: Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus

(Gene Expression)

PATENTS 

Jurisdiction Title Patent No. Issue Date
Argentina Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus AR043398 November 30, 2011
Australia Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus 2004216231 November 5, 2009
Canada Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus 2517384 January 22, 2013
EP (validated in Austria, Belgium, Switzerland, Lichtenstein, Germany, France, UK, Spain, Netherlands and Sweden) Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus 1597353 November 30, 2011
Israel Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus 170217 March 31, 2011
Korea Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus 10-1109062 January 17, 2012
Mexico Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus 280353 October 26, 2010
New Zealand Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus 542500 February 20, 2004
Taiwan Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus I346701 August 11, 2011

 


Discover Cancer Genetics Incorporated »

Our Research
With unparalleled excellence in oncology, our team is dedicated to empowering personalized cancer treatment.
Our Media
Stay current with the latest company news, articles, videos, and webinars.
Our Partners
CGI has established strong research collaborations with key thought leaders in oncology and major cancer centers in the U.S. and abroad.
Reports
Click here to login and view your reports.